Studies have shown that past alcohol consumption reduces response rates in patients with chronic Hepatitis C treated with interferon monotherapy.
Dr Chang and colleagues conducted a single center study in patients undergoing treatment with pegylated interferon and ribavirin.
The research team clarified the importance of alcohol consumption on response rates in these patients.
The team calculated the median daily alcohol consumption, determined by previously validated method, as well as quartiles of alcohol consumption.
Univariate and binary logistic regression analyses were performed using treatment response status as the dependent variable.
| Predictors of response by regression analysis included non-genotype 1 status|
|Alimentary Pharmacology & Therapeutics|
The researchers reported that overall, in an intention-to-treat analysis, 34 of 115 patients responded to treatment.
Black patients, especially those with Hepatitis C virus genotype 1, high viral load and low alanine aminotransferase were significantly less likely to respond.
The team noted that predictors of response by regression analysis included alcohol less than 30 g/day, non-genotype 1 status and non-black race.
Dr Chang's team concluded, “Median daily alcohol use more than 30 g/day is associated with failure to respond to pegylated interferon and ribavirin for treatment of Hepatitis C.”
“Past alcohol use should be evaluated when considering treatment for Hepatitis C.”